Trial Profile
Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Cyclophosphamide; Leukocyte cell therapy Leap Therapeutics; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Adverse reactions
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.